EUCTR2011-000440-22-NO进行中（未招募）不适用
MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI - EURO-SKI
niversity of Heidelberg0 个研究点目标入组 500 人开始时间: 2012年8月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •CML in CP under treatment with TKI in first line or in second line because of toxicity to first line TKI or with TKI in combination
- •Duration of TKI treatment before enrolment at least 3 years
- •Complete molecular remission (CMR4 (= 0.01% on IS) for at least one year; at least three PCR-results with CMR4 within the last year (± 2 months) before study entry
- •Before inclusion confirmation of CMR through a EUTOS-CMR laboratory
- •Both sexes but fertile women only if using effective contraceptive
- •Health insurance coverage
- •18 years or older
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •Under 18 years old
- •Hospitalized patients without ability to give informed consent
- •Adults under law protection or without ability to assent
- •Previous or planned allogeneic stem cell transplantation
研究者
相似试验
进行中（未招募）
1 期
EnglishEUCTR2011-000440-22-CZFakultní nemocnice Brno500
招募中
不适用
MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKIChronic Myeloid Leukaemia10024324NL-OMON39316Vrije Universiteit Medisch Centrum50
进行中（未招募）
不适用
ESTIMATING THE IMPACT OF STOPPING TKI IN CHRONIC MYELOID LEUKEMIAEUCTR2011-000440-22-SEniversity of Heidelberg700
进行中（未招募）
不适用
ESTIMATING THE IMPACT OF STOPPING TKI IN CHRONIC MYELOID LEUKEMIAEUCTR2011-000440-22-NLVU University Medical Center500
进行中（未招募）
1 期
ESTIMATING THE IMPACT OF STOPPING TKI IN CHRONIC MYELOID LEUKEMIAPatients with chronic myeloid leukemia with complete molecular response can stop tyrosine kinase inhibitors under close monitoringMedDRA version: 20.0Level: LLTClassification code 10009016Term: Chronic myeloid leukemia in remissionSystem Organ Class: 100000012996EUCTR2011-000440-22-DKniversity of Heidelberg500